Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

10.82 -0.02 (-0.18%)
Streaming Delayed Price Updated: 11:22 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For 4D Molecular Therapeutics's Future ↗
 
Via Benzinga
News headline image
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate ↗
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
Via Benzinga
News headline image
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
4DMT Announces Presentations at Upcoming Retina Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024 ↗
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate ↗
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... 
Via Benzinga
News headline image
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.